EF Hutton initiated coverage of Biomea Fusion with a Buy rating and $128 price target Biomea is developing small-molecule, irreversible, covalent inhibitors of validated drug targets for the treatment of diabetes and certain cancers, including lead program BMF-219. The inhibition of menin represents a novel therapeutic approach in diabetes and, if successful, BMF-219 could “change the treatment paradigm of diabetes,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA:
- Biomea Fusion forms Global Scientific Advisory Board
- Wynn Resorts upgraded, HP Inc. downgraded: Wall Street’s top analyst calls
- Biomea Fusion price target raised to $41 from $21 at Scotiabank
- Biomea Fusion price target raised to $40 from $15 at H.C. Wainwright
- Biomea Fusion upgraded to Buy from Hold at Truist